Travoprost
Systematic (IUPAC) name | |
---|---|
propan-2-yl 7-[3,5-dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl) phenoxy]-but-1-enyl]-cyclopentyl]hept-5-enoate | |
Clinical data | |
Trade names | Travatan |
AHFS/Drugs.com | monograph |
MedlinePlus | a602027 |
Pregnancy cat. | C US |
Legal status | Rx only (US) |
Routes | Topical (eye drops) |
Identifiers | |
CAS number | 157283-68-6 |
ATC code | S01EE04 |
PubChem | CID 5282226 |
DrugBank | DB00287 |
ChemSpider | 4445407 |
UNII | WJ68R08KX9 |
KEGG | D01964 |
ChEBI | CHEBI:746859 |
ChEMBL | CHEMBL1200799 |
Chemical data | |
Formula | C26H35F3O6 |
Mol. mass | 500.548 g/mol |
SMILES
| |
| |
(what is this?) (verify) | |
Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a synthetic prostaglandin analog (or more specifically, an analog of prostaglandin F2α)[1][2] that works by increasing the outflow of aqueous fluid from the eyes.[3] It is also known by the brand names of Travatan and Travatan Z, manufactured by Alcon, and Travo-Z, manufactured by Micro Labs.
Side effects
Possible side effects of this medication are:
- May cause blurred vision
- May cause eyelid redness
- May permanently darken eyelashes
- May cause eye discomfort
- May eventually cause permanent darkening of the iris to brown (heterochromia)
- May cause a temporary burning sensation during use
- May cause thickening of the eyelashes
- May cause inflammation of the prostate gland, restricting urine flow (BPH)
References
- ↑ Alcon Laboratories, Inc. (September 2011). "TRAVATAN - travoprost solution". DailyMed. Bethesda, MD: U.S. National Library of Medicine. Retrieved 2011-09-30.
- ↑ Alcon Laboratories, Inc. (September 2011). "TRAVATAN Z (travoprost) solution". DailyMed. Bethesda, MD: U.S. National Library of Medicine. Retrieved 2011-09-30.
- ↑ AHFS Consumer Medication Information (2011-01-01). "Travoprost Ophthalmic". MedlinePlus. Bethesda, MD: U.S. National Library of Medicine. Retrieved 2011-09-30.
|
|